South Korean COVID jab enters final stages of testing

1 September 2021
asia_asian_lab_research_biotech_big

Another coronavirus vaccine is moving towards the finishing line, as South Korean firm SK Bioscience (KRX: 302440) announced the initiation of Phase III tests for its candidate, GBP510.

Working with GlaxoSmithKline (LSE: GSK), SK is aiming to deliver a novel nanoparticle vaccine which targets the receptor binding domain of the virus.

GBP510 is being developed in combination with GSK’s pandemic adjuvant, and boasts positive interim Phase I/II results, generating strong neutralizing antibodies in trial participants.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology